Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
The study cohort consisted of RMS patients identified in the Adelphi Real World MS DSP, which was current up until the Q2/2021. The study was using waves VI-IX of the Adelphi DSP dataset.
Study period: Q1 2017 - Q1 \& Q2 2021 (waves VI-IX of Adelphi DSP dataset).
Identification period: Q1 2017 - Q1 \& Q2 2021 (waves VI-IX of Adelphi DSP dataset).
Index date: defined as the dates when the surveys were carried out (Q1 2017 - Q1 \& Q2 2021).
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients included in the database with a diagnosis of RRMS and SPMS.
Patients with current treatment at the index date.
Patients with previous treatment at the index date.
Patients to whom the physician decided to switch the treatment from the previous treatment to current treatment at the index date.
Patients (males \& females) with 18 years or older at index date.
You may not be if
Patients included in the database with the diagnosis of primary progressive MS (PPMS).
Patients with other major neurological or psychiatric condition, which could potentially hinder the analysis.
